ArticleAAPS PharmSciTech2019

Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells.

Ketan Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.